IL163667A0 - Novel sustained release pharmaceutical compounds to preventabuse of controlled substances - Google Patents
Novel sustained release pharmaceutical compounds to preventabuse of controlled substancesInfo
- Publication number
- IL163667A0 IL163667A0 IL16366703A IL16366703A IL163667A0 IL 163667 A0 IL163667 A0 IL 163667A0 IL 16366703 A IL16366703 A IL 16366703A IL 16366703 A IL16366703 A IL 16366703A IL 163667 A0 IL163667 A0 IL 163667A0
- Authority
- IL
- Israel
- Prior art keywords
- preventabuse
- sustained release
- release pharmaceutical
- pharmaceutical compounds
- controlled substances
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35836802P | 2002-02-22 | 2002-02-22 | |
US36208202P | 2002-03-07 | 2002-03-07 | |
PCT/US2003/005525 WO2003072046A2 (fr) | 2002-02-22 | 2003-02-24 | Nouveaux composes pharmaceutiques a liberation prolongee destines a empecher la consommation abusive de substances controlees |
Publications (1)
Publication Number | Publication Date |
---|---|
IL163667A0 true IL163667A0 (en) | 2005-12-18 |
Family
ID=27767540
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16366703A IL163667A0 (en) | 2002-02-22 | 2003-02-24 | Novel sustained release pharmaceutical compounds to preventabuse of controlled substances |
IL163667A IL163667A (en) | 2002-02-22 | 2004-08-22 | Conjugates comprising controlled substances covalently bound to peptides or amino acids and compositions comprising same |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL163667A IL163667A (en) | 2002-02-22 | 2004-08-22 | Conjugates comprising controlled substances covalently bound to peptides or amino acids and compositions comprising same |
Country Status (9)
Country | Link |
---|---|
US (1) | US7622441B2 (fr) |
EP (2) | EP1531844B1 (fr) |
JP (1) | JP4878732B2 (fr) |
KR (1) | KR100822498B1 (fr) |
AU (2) | AU2003219863C1 (fr) |
CA (1) | CA2477004C (fr) |
ES (1) | ES2500117T3 (fr) |
IL (2) | IL163667A0 (fr) |
WO (1) | WO2003072046A2 (fr) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6716452B1 (en) * | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
US20070060500A1 (en) * | 2000-08-22 | 2007-03-15 | New River Pharmaceuticals Inc. | Pharmaceutical compositions for prevention of overdose or abuse |
US20090306228A1 (en) * | 2000-11-14 | 2009-12-10 | Shire Llc | Active agent delivery systems and methods for protecting and administering active agents |
US8394813B2 (en) | 2000-11-14 | 2013-03-12 | Shire Llc | Active agent delivery systems and methods for protecting and administering active agents |
US7169752B2 (en) * | 2003-09-30 | 2007-01-30 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
US7375082B2 (en) * | 2002-02-22 | 2008-05-20 | Shire Llc | Abuse-resistant hydrocodone compounds |
US20070066537A1 (en) * | 2002-02-22 | 2007-03-22 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
US20060014697A1 (en) * | 2001-08-22 | 2006-01-19 | Travis Mickle | Pharmaceutical compositions for prevention of overdose or abuse |
US7338939B2 (en) * | 2003-09-30 | 2008-03-04 | New River Pharmaceuticals Inc. | Abuse-resistant hydrocodone compounds |
US20040156844A1 (en) * | 2002-05-22 | 2004-08-12 | Curtis Wright | Tamper resistant oral dosage form |
US6913768B2 (en) * | 2002-09-24 | 2005-07-05 | Shire Laboratories, Inc. | Sustained release delivery of amphetamine salts |
AU2004204804C1 (en) * | 2003-01-13 | 2010-11-18 | Shire Llc | Carbohydrate conjugates to prevent abuse of controlled substances |
US8133881B2 (en) | 2003-01-13 | 2012-03-13 | Shire Llc | Carbohydrate conjugates to prevent abuse of controlled substances |
US7230005B2 (en) * | 2003-03-13 | 2007-06-12 | Controlled Chemicals, Inc. | Compounds and methods for lowering the abuse potential and extending the duration of action of a drug |
US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
SI1644019T2 (en) * | 2003-05-29 | 2018-04-30 | Shire Llc | AMPHETAMINE COMPOUNDS COMPOUNDS TO ABUSE |
AU2004277400B2 (en) * | 2003-09-30 | 2009-01-22 | Shire Llc | Pharmaceutical compositions for prevention of overdose or abuse |
US20050196455A1 (en) * | 2003-10-27 | 2005-09-08 | Jianbing Chen | Suspension delivery system for the sustained and controlled local release of pharmaceuticals |
AU2005304751A1 (en) * | 2004-11-08 | 2006-05-18 | Shire Llc | Synergistic effects of combined administration of mirtazapine and a stimulant compound |
US20060135906A1 (en) * | 2004-11-16 | 2006-06-22 | Akihiko Matsumura | Iontophoretic device and method for administering immune response-enhancing agents and compositions |
JP2006296511A (ja) * | 2005-04-15 | 2006-11-02 | Transcutaneous Technologies Inc | 外用剤、外用剤の塗布方法、イオントフォレーシス装置及び経皮パッチ |
AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
WO2007041322A2 (fr) * | 2005-09-30 | 2007-04-12 | Tti Ellebeau, Inc. | Apport ionophoretique d'agents actifs conjugues a des nanoparticules |
JP2009509677A (ja) * | 2005-09-30 | 2009-03-12 | Tti・エルビュー株式会社 | 小胞封入活性物質のイオントフォレーシス送達 |
US20070135754A1 (en) * | 2005-09-30 | 2007-06-14 | Hidero Akiyama | Electrode assembly for iontophoresis for administering active agent enclosed in nanoparticle and iontophoresis device using the same |
US20070083186A1 (en) * | 2005-09-30 | 2007-04-12 | Darrick Carter | Transdermal drug delivery systems, devices, and methods employing novel pharmaceutical vehicles |
JP2009522011A (ja) * | 2005-12-30 | 2009-06-11 | Tti・エルビュー株式会社 | 活性物質を生体界面に送達するイオントフォレーシスシステム、装置及び方法 |
JP2009533459A (ja) * | 2006-04-14 | 2009-09-17 | シャイア エルエルシー | 共有結合する化合物の鎮痛作用の増強と、有害な副作用の減衰と、前記化合物の乱用の予防とのための組成物及び方法 |
SG172633A1 (en) * | 2006-05-26 | 2011-07-28 | Pharmacofore Inc | Controlled release of phenolic opioids |
US20080207668A1 (en) * | 2006-10-06 | 2008-08-28 | New River Pharmaceuticals Inc. | Pharmaceutical compositions of hydromorphone for prevention of overdose or abuse |
JP2010522135A (ja) * | 2006-10-09 | 2010-07-01 | チャールストン ラボラトリーズ,インコーポレイテッド | 医薬組成物 |
US20080193514A1 (en) * | 2006-11-02 | 2008-08-14 | Transcu Ltd. | Compostions and methods for iontophoresis delivery of active ingredients through hair follicles |
ATE509622T1 (de) | 2006-12-11 | 2011-06-15 | Kempharm Inc | Amphetamin-ornithine konjugate sowie herstellungs-und verwendungsverfahren |
JPWO2008087803A1 (ja) * | 2007-01-16 | 2010-05-06 | 国立大学法人北海道大学 | 抗酸化成分を封入したイオントフォレーシス用リポソーム製剤 |
ATE552861T1 (de) | 2007-02-08 | 2012-04-15 | Kempharm Inc | Polare hydrophile prodrugs von amphetamin und anderen stimulantien sowie herstellungs- und verwendungsverfahren |
WO2008101187A2 (fr) * | 2007-02-16 | 2008-08-21 | Pharmacofore, Inc. | Pro-médicaments d'antagonistes opioïdes phénoliques périphériques |
MX2009012273A (es) * | 2007-05-18 | 2010-04-09 | Tti Ellebeau Inc | Dispositivos de suministro transd?rmico que aseguran la liberaci?n mejorada de un principio activo a trav?s de una interfaz biol?gica. |
JP2010187707A (ja) * | 2007-06-12 | 2010-09-02 | Hokkaido Univ | インスリンを封入したイオントフォレーシス用リポソーム製剤 |
CA2696341C (fr) | 2007-08-13 | 2016-05-17 | Abuse Deterrent Pharmaceutical Llc | Medicaments resistant aux abus, procedes d'utilisation et de fabrication |
US9023860B2 (en) | 2007-11-26 | 2015-05-05 | Signature Therapeutics, Inc. | Pro-drugs for controlled release of biologically active compounds |
JP5714910B2 (ja) | 2008-01-09 | 2015-05-07 | チャールストン ラボラトリーズ,インコーポレイテッド | 薬学的組成物 |
AU2009291764A1 (en) * | 2008-09-10 | 2010-03-18 | Transcu Ltd. | Apparatus and method to dispense HPC-based viscous liquids into porous substrates, e.g., continuous web-based process |
US8460640B2 (en) | 2008-12-12 | 2013-06-11 | Paladin Labs, Inc. | Narcotic drug formulations with decreased abuse potential |
EP2381937A2 (fr) | 2008-12-31 | 2011-11-02 | Upsher-Smith Laboratories, Inc. | Compositions pharmaceutiques orales contenant un opioïde et procédés |
UA102916C2 (uk) * | 2009-07-02 | 2013-08-27 | Кемфарм, Інк. | Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань |
US10849981B2 (en) | 2009-07-02 | 2020-12-01 | KemPham, Inc. | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof |
US20120142720A1 (en) | 2009-07-02 | 2012-06-07 | Kempharm, Inc. | Phenylethanoic Acid, Phenylpropanoic Acid and Phenylpropenoic Acid Conjugates and Prodrugs of Hydrocodone, Methods of Making and Use Thereof |
CA2767576C (fr) | 2009-07-08 | 2020-03-10 | Charleston Laboratories Inc. | Compositions pharmaceutiques refermant un antiemetique et un analgesiqueopioide |
US20120270847A1 (en) | 2009-07-17 | 2012-10-25 | Shire Llc | Novel carbamate amino acid and peptide prodrugs of opiates and uses thereof |
EP2477610A1 (fr) | 2009-09-17 | 2012-07-25 | Upsher-Smith Laboratories, Inc. | Produit à libération prolongée comprenant une combinaison d'une amine non opioïde et d'un médicament anti-inflammatoire non stéroïdal |
ES2710617T3 (es) | 2010-04-21 | 2019-04-26 | Signature Therapeutics Inc | Composiciones que comprenden profármacos de anfetamina escindibles enzimáticamente e inhibidores de los mismos |
US20110262355A1 (en) | 2010-04-21 | 2011-10-27 | Jenkins Thomas E | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof |
WO2011133346A1 (fr) * | 2010-04-21 | 2011-10-27 | Pharmacofore, Inc. | Agonistes opiacés périphériques et antagonistes opiacés périphériques |
DK2663187T3 (en) | 2011-01-11 | 2016-08-29 | Signature Therapeutics Inc | Compositions comprising enzyme-cleavable oxycodone prodrug |
US8685916B2 (en) | 2011-03-09 | 2014-04-01 | Signature Therapeutics, Inc. | Opioid prodrugs with heterocyclic linkers |
RU2608305C2 (ru) | 2011-03-09 | 2017-01-17 | Сигничер Терапьютикс, Инк. | Пролекарства действующих веществ гетероциклическими линкерами |
US10420726B2 (en) | 2013-03-15 | 2019-09-24 | Inspirion Delivery Sciences, Llc | Abuse deterrent compositions and methods of use |
CA2961460A1 (fr) * | 2014-09-15 | 2016-03-24 | Inspirion Delivery Technologies, Llc | Composition pour administration orale et procedes de prevention des addictions par administration intranasale |
US10729685B2 (en) | 2014-09-15 | 2020-08-04 | Ohemo Life Sciences Inc. | Orally administrable compositions and methods of deterring abuse by intranasal administration |
NZ731591A (en) | 2014-11-25 | 2018-06-29 | Kempharm Inc | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone |
US10017519B2 (en) * | 2015-04-27 | 2018-07-10 | 3St Research Llc | Alpha-hydroxy carboxylic acid and derivatives and other GRAS based prodrugs of oxycodone and uses thereof |
US10449190B2 (en) | 2015-04-27 | 2019-10-22 | John K. Thottathil | Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of opioids and uses thereof |
US9987269B2 (en) | 2015-04-27 | 2018-06-05 | 3St Research Llc | Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of oxymorphone and uses thereof |
US10226456B2 (en) | 2015-04-27 | 2019-03-12 | 3St Research Llc | Methods and compositions for preventing opioid abuse |
EP3423041A4 (fr) | 2016-03-04 | 2019-09-11 | Charleston Laboratories, Inc. | Compositions pharmaceutiques |
AU2018234911B2 (en) * | 2017-03-17 | 2024-04-18 | Elysium Therapeutics, Inc. | Polysubunit opioid prodrugs resistant to overdose and abuse |
MX2020000638A (es) | 2017-07-20 | 2020-07-29 | Suzhou Runxindatai Pharmaceutics Ltd Co | Profármacos opioides de acción prolongada resistentes al abuso. |
MX2020008706A (es) | 2018-02-23 | 2020-09-25 | Rhodes Tech | Nuevos compuestos de opioides y sus usos. |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2507631A (en) | 1944-01-19 | 1950-05-16 | Ciba Pharm Prod Inc | Pyridine and piperidine compounds and process of making same |
DE1493824A1 (de) * | 1964-01-27 | 1969-05-22 | Hoffmann La Roche | Verfahren zur Herstellung von Aminocarbonsaeureamiden |
CH406567A (de) | 1964-02-10 | 1966-01-31 | Inventio Ag | Einrichtung zur Steuerung der Sollwertgrösse während des Verzögerungsvorganges bei Aufzügen mit drehzahlgeregeltem Antrieb |
GB1112347A (en) | 1965-08-20 | 1968-05-01 | Pierre Wirth | Salts of organic bases with n-carbamyl-l-glutamic acid |
US3846399A (en) | 1969-04-10 | 1974-11-05 | Merck & Co Inc | Process for controlled stepwise synthesis of polypeptides |
US3975342A (en) | 1972-05-15 | 1976-08-17 | Biological Developments, Inc. | Tyrosyl-class antigenic conjugates, their preparation and antibodies raised thereto |
US3884898A (en) | 1972-08-18 | 1975-05-20 | Syva Co | Normorphine derivatives bonded to proteins |
US3843696A (en) * | 1972-09-05 | 1974-10-22 | Syva Co | Methadone analog compounds |
US3878187A (en) * | 1972-09-11 | 1975-04-15 | Syva Co | Polypeptide derivatives of amphetamine and analogs for immunoassays |
US3998799A (en) | 1973-11-02 | 1976-12-21 | Interx Research Corporation | Novel, transient pro-drug forms of l-dopa |
US4040907A (en) | 1974-06-20 | 1977-08-09 | Syva Company | Iodothyronine enzyme conjugates |
US4025501A (en) * | 1975-03-20 | 1977-05-24 | Syva Company | Polypeptide propoxyphene derivatives for immunoassay reagents |
GB1592552A (en) | 1976-12-10 | 1981-07-08 | Inst Nat Sante Rech Med | Pseudopeptides used as medicaments |
US4356166A (en) | 1978-12-08 | 1982-10-26 | University Of Utah | Time-release chemical delivery system |
US4399121A (en) | 1981-11-04 | 1983-08-16 | Miles Laboratories, Inc. | Iodothyronine immunogens and antibodies |
US4427660A (en) | 1982-03-03 | 1984-01-24 | Research Corporation | Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections |
HU185535B (en) | 1982-05-25 | 1985-02-28 | Mta Koezponti Hivatala | Process for preparing new gonadoliberin derivatives |
US4457907A (en) | 1982-08-05 | 1984-07-03 | Clear Lake Development Group | Composition and method for protecting a therapeutic drug |
US4650675A (en) | 1983-08-18 | 1987-03-17 | The Children's Medical Center Corporation | Oligonucleotide conjugates |
EP0179023B1 (fr) | 1984-10-19 | 1991-01-23 | Battelle Memorial Institute | Polypeptide biodégradable et son utilisation pour le relargage progressif de médicaments |
GB8500209D0 (en) | 1985-01-04 | 1985-02-13 | Ceskoslovenska Akademie Ved | Synthetic polymeric drugs |
US4863735A (en) | 1985-02-19 | 1989-09-05 | Massachusetts Institute Of Technology | Biodegradable polymeric drug delivery system with adjuvant activity |
US4801575A (en) | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
IN165717B (fr) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
DK406686D0 (da) | 1986-08-26 | 1986-08-26 | Hans Bundgaard | Carboxylsyrederivater |
US5169933A (en) | 1988-08-15 | 1992-12-08 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
US5026827A (en) | 1988-09-02 | 1991-06-25 | Matsushita Electric Industrial Co., Ltd. | Amphetamine-protein complex as immunogen for obtaining antibodies specific to methamphetamine |
US4960790A (en) | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
US5767227A (en) | 1989-11-03 | 1998-06-16 | Lotus Biochemical Corp. | Iodothyronine polymers |
US5219564A (en) | 1990-07-06 | 1993-06-15 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
EP0477931B1 (fr) | 1990-09-28 | 1994-08-17 | Mercian Corporation | Dérivés d'adriamycin |
US5238714A (en) | 1990-10-02 | 1993-08-24 | Board Of Regents, The University Of Texas System | Efficient microcapsule preparation and method of use |
US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
CA2096495C (fr) | 1992-06-16 | 2002-07-09 | Kathy Palmer Ordonez | Dosage immunologique pour deux analytes |
GB9213077D0 (en) | 1992-06-19 | 1992-08-05 | Erba Carlo Spa | Polymerbound taxol derivatives |
US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
GB9215780D0 (en) | 1992-07-24 | 1992-09-09 | Univ London Pharmacy | Peptide compounds |
US6093391A (en) | 1992-10-08 | 2000-07-25 | Supratek Pharma, Inc. | Peptide copolymer compositions |
IL107400A0 (en) | 1992-11-10 | 1994-01-25 | Cortech Inc | Bradykinin antagonists |
US5298410A (en) | 1993-02-25 | 1994-03-29 | Sterling Winthrop Inc. | Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life |
US5891459A (en) | 1993-06-11 | 1999-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
AU5722694A (en) | 1993-11-05 | 1995-05-23 | Astra Aktiebolag | Novel amino acid derivatives |
AU5825094A (en) | 1993-11-19 | 1995-06-06 | Astra Aktiebolag | Novel dipeptide derivatives |
GB9401891D0 (en) | 1994-02-01 | 1994-03-30 | Boots Co Plc | Therapeutic agents |
US5847436A (en) * | 1994-03-18 | 1998-12-08 | Kabushiki Kaisha Tokai Rika Denki Seisakusho | Bipolar transistor having integrated thermistor shunt |
US5716614A (en) | 1994-08-05 | 1998-02-10 | Molecular/Structural Biotechnologies, Inc. | Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier |
US5910569A (en) | 1994-11-22 | 1999-06-08 | Lotus Biochemical Corporation | Iodothyronine polymers |
US5846743A (en) | 1995-02-22 | 1998-12-08 | Brigham And Women's Hospital, Inc. | Polyphoshoinositide binding peptides for intracellular drug delivery |
US5710256A (en) | 1995-04-03 | 1998-01-20 | Biosite Diagnostics Incorporated | Methadone derivatives and protein and polypeptide methadone derivative conjugates and labels |
US5670477A (en) | 1995-04-20 | 1997-09-23 | Joseph F. Poduslo | Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents |
DE69612093T2 (de) | 1995-06-07 | 2001-10-31 | Joel K Swadesh | Auf antigen verarbeitende zellen zielgerichtete konjugate ein polyaminosäure rückgrat und ein nicht-steroidales antiphlogistikum enthaltend |
US5762909A (en) | 1995-08-31 | 1998-06-09 | General Electric Company | Tumor targeting with polymeric molecules having extended conformation |
US5851536A (en) | 1995-11-22 | 1998-12-22 | University Of Washington | Therapeutic delivery using compounds self-assembled into high axial ratio microstructures |
US5922736A (en) | 1995-12-04 | 1999-07-13 | Celegene Corporation | Chronic, bolus administration of D-threo methylphenidate |
AU735900B2 (en) | 1996-03-12 | 2001-07-19 | Pg-Txl Company, L.P. | Water soluble paclitaxel prodrugs |
GB9606975D0 (en) | 1996-04-02 | 1996-06-05 | Univ Birmingham | Anti-tumor agent |
US6030941A (en) | 1996-05-01 | 2000-02-29 | Avi Biopharma, Inc. | Polymer composition for delivering substances in living organisms |
US5970477A (en) * | 1996-07-15 | 1999-10-19 | Bellsouth Intellectual Property Management Corporation | Method and system for allocating costs in a distributed computing network |
US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
US5952294A (en) | 1996-07-31 | 1999-09-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptidyl prodrugs and methods of making and using the same |
US6013633A (en) | 1997-08-07 | 2000-01-11 | University Of Cincinnati | Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm |
US5948750A (en) | 1996-10-30 | 1999-09-07 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
ATE251913T1 (de) | 1997-05-21 | 2003-11-15 | Univ Leland Stanford Junior | Zusammensetzung und verfahren zur verzögerung des transports durch biologische membranen |
TW460478B (en) | 1997-08-15 | 2001-10-21 | Chugai Pharmaceutical Co Ltd | Phenethylamine derivatives |
AU1825299A (en) | 1997-12-17 | 1999-07-05 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
TR200001828T2 (tr) * | 1997-12-22 | 2000-11-21 | Euro-Celtique, S.A. | Opioid dozaj şekillerinin kötüye kullanımını önlemeye yönelik bir yöntem. |
JP2002501923A (ja) | 1998-01-29 | 2002-01-22 | モナシュ ユニバーシティ | 治療用化合物 |
US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
US6652864B1 (en) | 1998-12-21 | 2003-11-25 | Asilomar Pharmaceuticals, Inc. | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6716452B1 (en) * | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
AU3699000A (en) * | 1999-03-10 | 2000-09-28 | Lotus Biochemical Corporation | Use of protein conformation for the protection and release of chemical compounds |
US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
JP2003522127A (ja) * | 1999-07-29 | 2003-07-22 | ロクセニ ラボラトリーズ インコーポレイテッド | オピオイド徐放性製剤 |
GEP20053614B (en) * | 2000-02-08 | 2005-09-26 | Euro Celtique Sa | Compositions for Oral Administration Containing Opioid Agonist |
US20020099013A1 (en) * | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
US20020098999A1 (en) | 2000-10-06 | 2002-07-25 | Gallop Mark A. | Compounds for sustained release of orally delivered drugs |
US20020151526A1 (en) | 2000-10-06 | 2002-10-17 | Gallop Mark A. | Bile-acid prodrugs of L-dopa and their use in the sustained treatment of parkinsonism |
WO2002028881A1 (fr) | 2000-10-06 | 2002-04-11 | Xenoport, Inc. | Composes derives d'acide biliaire assurant des concentrations systemiques prolongees de medicaments apres administration par voie orale |
US6740641B2 (en) | 2001-07-27 | 2004-05-25 | Euro-Celtique, S.A. | Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain |
US20030091593A1 (en) * | 2001-09-14 | 2003-05-15 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
US7230005B2 (en) | 2003-03-13 | 2007-06-12 | Controlled Chemicals, Inc. | Compounds and methods for lowering the abuse potential and extending the duration of action of a drug |
-
2003
- 2003-02-24 AU AU2003219863A patent/AU2003219863C1/en not_active Ceased
- 2003-02-24 IL IL16366703A patent/IL163667A0/xx active IP Right Grant
- 2003-02-24 EP EP03716144.5A patent/EP1531844B1/fr not_active Expired - Lifetime
- 2003-02-24 ES ES03716144.5T patent/ES2500117T3/es not_active Expired - Lifetime
- 2003-02-24 KR KR1020047013136A patent/KR100822498B1/ko active IP Right Grant
- 2003-02-24 EP EP11151658A patent/EP2319540A1/fr not_active Withdrawn
- 2003-02-24 WO PCT/US2003/005525 patent/WO2003072046A2/fr active Application Filing
- 2003-02-24 CA CA2477004A patent/CA2477004C/fr not_active Expired - Fee Related
- 2003-02-24 JP JP2003570793A patent/JP4878732B2/ja not_active Expired - Fee Related
-
2004
- 2004-08-22 IL IL163667A patent/IL163667A/en not_active IP Right Cessation
- 2004-08-23 US US10/923,257 patent/US7622441B2/en not_active Expired - Fee Related
-
2008
- 2008-10-16 AU AU2008229978A patent/AU2008229978B2/en not_active Withdrawn - After Issue
Also Published As
Publication number | Publication date |
---|---|
AU2008229978A1 (en) | 2008-11-06 |
AU2003219863A1 (en) | 2003-09-09 |
EP1531844A4 (fr) | 2007-06-13 |
JP4878732B2 (ja) | 2012-02-15 |
US7622441B2 (en) | 2009-11-24 |
JP2005524648A (ja) | 2005-08-18 |
EP1531844A2 (fr) | 2005-05-25 |
US20050080012A1 (en) | 2005-04-14 |
WO2003072046A3 (fr) | 2005-03-10 |
CA2477004C (fr) | 2011-05-10 |
KR100822498B1 (ko) | 2008-04-16 |
WO2003072046A2 (fr) | 2003-09-04 |
CA2477004A1 (fr) | 2003-09-04 |
ES2500117T3 (es) | 2014-09-30 |
AU2003219863C1 (en) | 2009-03-05 |
EP1531844B1 (fr) | 2014-08-20 |
IL163667A (en) | 2011-03-31 |
AU2008229978B2 (en) | 2012-03-22 |
EP2319540A1 (fr) | 2011-05-11 |
KR20040095228A (ko) | 2004-11-12 |
AU2003219863B2 (en) | 2008-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL163667A0 (en) | Novel sustained release pharmaceutical compounds to preventabuse of controlled substances | |
HK1257298A1 (zh) | 硼的酯和酸化合物的合成 | |
IL173930A0 (en) | Pharmaceutical compositions containing forms of r-baclofen | |
HK1076734A1 (en) | Tablets containing 250 to 450 mg of modafinil | |
ZA200508204B (en) | Pharmaceutical composition of atorvastatin | |
IL173858A0 (en) | Process for preparation of rosuvastatin calcium | |
EP1664627A4 (fr) | Application fonctionnelle de materiaux a base de composes photochromes a des produits | |
AU2003290734A1 (en) | Novel compounds as pharmaceutical agents | |
IL166108A0 (en) | Novel compounds pharmaceutical compositions containing same and methods of use for same | |
EP1424994A4 (fr) | Preparation d'une composition pharmaceutique a liberation prolongee | |
IL180031A0 (en) | Stable pharmaceutical formulations of benzimidazole compounds | |
AU2003260803A8 (en) | Sustained release pharmaceutical composition | |
GB0305150D0 (en) | Use of therapeutic compounds | |
ZA200407609B (en) | Use of vitamin d compounds | |
IL166054A0 (en) | Novel compounds pharmaceutical compositions containing same and methods of use for same | |
PL376840A1 (pl) | Kompozycja farmaceutyczna o przedłużonym uwalnianiu | |
GB0202900D0 (en) | Novel formulations of drugs | |
EP1539780A4 (fr) | Derives de monosaccharides utilises pour la decouverte de medicaments | |
EP1478353A4 (fr) | Composition pharmaceutique a liberation soutenue | |
AU2003291642A8 (en) | Pyrazoloazepine compounds as pharmaceutical agents | |
PL1656358T3 (pl) | Trwały polimorf mesylanu bifeprunoksu | |
GB0327742D0 (en) | Novel uses of known drugs | |
GB2406517B (en) | Minocycline controlled release pharmaceutical composition | |
GB2404856B (en) | Stable pharmaceutical composition of rabeprazole | |
HU0200337D0 (en) | Stabilised pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed |